市場調査レポート
商品コード
1162477

血液腫瘍検査の世界市場:製品/サービス別 (サービス、アッセイキット)・がん別 (白血病 (急性骨髄性、急性リンパ性)、リンパ腫 (非ホジキン、ホジキン)・技術別 (PCR、NGS)・エンドユーザー別の将来予測 (2027年まで)

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 141 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
血液腫瘍検査の世界市場:製品/サービス別 (サービス、アッセイキット)・がん別 (白血病 (急性骨髄性、急性リンパ性)、リンパ腫 (非ホジキン、ホジキン)・技術別 (PCR、NGS)・エンドユーザー別の将来予測 (2027年まで)
出版日: 2022年11月23日
発行: MarketsandMarkets
ページ情報: 英文 141 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の血液腫瘍検査の市場規模は、2022年の29億米ドルから2027年には56億米ドルに達し、14.2%のCAGRで成長すると予測されます。

この市場の成長は、血液がんの発生率の増加、共同研究の増加、個別化医療に関する会議の増加などに起因するものです。

"製品・サービスの種類別では、予測期間中、サービス分野が最も高い成長率を占めた"

2021年には、サービス分野が世界の血液腫瘍検査市場で最大のシェアを占めています。これは、血液がんの発症件数が大幅に増加していることに起因することができます。したがって、患者は治療中に継続的なモニタリング・検査を必要とし、血液がんの臨床試験を実施するための企業間の増加傾向により血液腫瘍検査製品が必要とあり、診断テスト手順のための診断センターの増加は、血液腫瘍検査製品市場におけるサービスセグメントの需要を後押しすると予想されます。

"予測期間中、がんの種類別ではリンパ腫分野が最も高いCAGRを占める"

2021年では、リンパ腫セグメントが世界市場を独占しています。これは、リンパ腫の有病率の上昇や世界の老齢人口の増加が、リンパ腫の発症件数の増加を支えているなどの要因によるものです。

"技術の種類別では、PCR分野が最も高い成長率を占める"

2021年には、PCRのセグメントが血液腫瘍検査市場を独占しました。その要因として、その使いやすさとアッセイキットの入手のしやすさから、この技術が広く使用されていることが挙げられます。

"アジア太平洋は予測期間中に最も高いCAGRで成長する"

アジア太平洋の血液腫瘍検査市場は、予測期間中に高い成長を遂げることが期待されています。市場成長の要因には、高齢者人口の増加、質の高い医療に対する需要の増加、がんバイオマーカーに対する業界関係者の関心増大などが挙げられます。

当レポートでは、世界の血液腫瘍検査の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、製品/サービス別・がんの種類別・技術別・エンドユーザー別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 血液腫瘍検査市場:製品/サービス別

  • イントロダクション
  • サービス
  • アッセイキット

第7章 血液腫瘍検査市場:がんの種類別

  • イントロダクション
  • 白血病
    • 急性骨髄性白血病
    • 急性リンパ性白血病
    • その他の白血病
  • リンパ腫
    • 非ホジキンリンパ腫
    • ホジキンリンパ腫
  • その他のがん

第8章 血液腫瘍検査市場:技術別

  • イントロダクション
  • PCR (ポリメラーゼ連鎖反応)
  • IHC (免疫組織化学染色)
  • NGS (次世代シーケンス)
  • 細胞遺伝学
  • その他の技術

第9章 血液腫瘍検査市場:エンドユーザー別

  • イントロダクション
  • 臨床検査室
  • 病院
  • 教育・研究機関
  • その他のエンドユーザー

第10章 血液腫瘍検査市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア太平洋
  • 他の国々 (RoW)

第11章 競合情勢

  • 概要
  • 主要企業が採用した戦略/有力企業
  • 市場シェア分析 (2021年)
  • 企業評価マトリックス
  • 主要戦略
    • 製品の発売
    • 資本取引
    • その他の動向

第12章 企業プロファイル

  • 主要企業
    • ABBOTT LABORATORIES
    • F. HOFFMANN-LA ROCHE AG
    • QIAGEN N.V.
    • THERMO FISHER SCIENTIFIC, INC.
    • ILLUMINA, INC.
    • BIO-RAD LABORATORIES, INC.
    • MOLECULARMD (ICON PLCの子会社)
    • ADAPTIVE BIOTECHNOLOGIES
    • ARCHERDX, INC. (INVITAE CORPORATIONの子会社)
    • ARUP LABORATORIES, INC.
    • ASURAGEN, INC.
    • INVIVOSCRIBE, INC.
    • AMOY DIAGNOSTICS CO., LTD.
    • ELITECHGROUP
    • VELA DIAGNOSTICS
  • その他の企業
    • GENTRONIX LIMITED
    • BIOIVT
    • SAGA DIAGNOSTICS
    • OLINK
    • CANCER DIAGNOSTICS, INC.

第13章 付録

目次
Product Code: MD 7180

The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

"The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period"

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.

In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .

"Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period"

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.

"The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period"

Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.

In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.

"The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period."

The Hemato oncology testing market is segmented into - North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-45%, Tier 2-35%, and Tier 3- 45%
  • By Designation: C-level-32%, Director-level-20%, and Others-48%
  • By Region: North America-35%, Europe-28%, Asia Pacific-25%, ROW¬-12%

Lists of Companies Profiled in the Report:

  • Abbott Laboratories (US)
  • F. Hoffman-La Roche (Switzerland)
  • QIAGEN (Germany)
  • Thermo Fisher Scientific (US)
  • Illumina (US)
  • Bio-Rad Laboratories (US)q
  • MolecularMD (Ireland)
  • ArcherDX (US)
  • ARUP Laboratories (US)
  • Asuragen (US)
  • Invivoscribe (US)
  • Adaptive Biotechnologies (US)
  • Amoy Diagnostics (China)
  • ELITechGroup (France)
  • Vela Diagnostics (Singapore)
  • Gentronix (UK)
  • BioIVT (US)
  • SAGA Diagnostics (Sweden)
  • Olink (Sweden)
  • Cancer Diagnostics (US)

Research Coverage

This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • FIGURE 1 MARKETS COVERED
    • 1.3.1 REGIONAL SCOPE
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
    • 2.2.2 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
    • 2.3.1 KEY DATA FROM PRIMARY SOURCES
    • 2.3.2 KEY INDUSTRY INSIGHTS
  • 2.4 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.5 MARKET SIZE ESTIMATION
    • FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
    • 2.5.1 GROWTH FORECAST
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.5.2 TOP-DOWN APPROACH
    • FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
  • 2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.7 RESEARCH ASSUMPTIONS
  • 2.8 STUDY ASSUMPTIONS
  • 2.9 INDICATORS AND OTHER ASSUMPTIONS
  • 2.10 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT
  • 2.11 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW
    • FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021)
    • FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET
    • FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing incidence of hematologic cancer
    • TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020-2040
    • TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030
      • 5.2.1.2 Increasing collaborations between companies
      • 5.2.1.3 Rising number of private diagnostic centers
      • 5.2.1.4 Increasing conferences on personalized medicine
    • TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022-2023
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
      • 5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests
      • 5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
    • TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019
    • TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040
      • 5.2.3.2 Drug diagnostics co-development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Intellectual property rights protection issues
      • 5.2.4.2 Shortage of trained professionals

6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 SERVICES
    • 6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES
    • TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 6.3 ASSAY KITS
    • 6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH
    • TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION)

7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
    • TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
  • 7.2 LEUKEMIA
    • FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020
    • TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • 7.2.1 ACUTE MYELOID LEUKEMIA
      • 7.2.1.1 High incidence of AML in adults to drive growth
    • TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
      • 7.2.2.1 High incidence of ALL in children to support growth
    • TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.3 OTHER LEUKEMIAS
    • TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 LYMPHOMA
    • TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • 7.3.1 NON-HODGKIN LYMPHOMA
      • 7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period
    • FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020
    • TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 HODGKIN LYMPHOMA
      • 7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate
    • FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020
    • TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 OTHER CANCERS
    • TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020-2027 (USD MILLION)

8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 8.2 PCR
    • 8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET
    • TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 IHC
    • 8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION
    • TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 NGS
    • 8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    • TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 CYTOGENETICS
    • 8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH
    • TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020-2027 (USD MILLION)
  • 8.6 OTHER TECHNOLOGIES
    • TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)

9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 CLINICAL LABORATORIES
    • 9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET
    • TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 HOSPITALS
    • 9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH
    • TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH
    • TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period
    • TABLE 42 US: LEUKEMIA AT A GLANCE
    • TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market
    • TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET
    • TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    • FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
    • TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
    • TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET
  • 11.3 MARKET SHARE ANALYSIS, 2021
    • TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION
  • 11.4 COMPANY EVALUATION MATRIX
    • 11.4.1 STARS
    • 11.4.2 EMERGING LEADERS
    • 11.4.3 PERVASIVE PLAYERS
    • 11.4.4 PARTICIPANTS
    • FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
  • 11.5 KEY STRATEGIES
    • 11.5.1 PRODUCT LAUNCHES
    • TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019-NOVEMBER 2022
    • 11.5.2 DEALS
    • TABLE 81 KEY DEALS, JANUARY 2019-AUGUST 2022
    • 11.5.3 OTHER DEVELOPMENTS
    • TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019-NOVEMBER 2022

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ABBOTT LABORATORIES
    • TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 12.1.2 F. HOFFMANN-LA ROCHE AG
    • TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
    • 12.1.3 QIAGEN N.V.
    • TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.4 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.5 ILLUMINA, INC.
    • TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 BIO-RAD LABORATORIES, INC.
    • TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
    • TABLE 89 ICON PLC: BUSINESS OVERVIEW
    • FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021)
    • 12.1.8 ADAPTIVE BIOTECHNOLOGIES
    • TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
    • 12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)
    • TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW
    • 12.1.10 ARUP LABORATORIES, INC.
    • TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW
    • 12.1.11 ASURAGEN, INC.
    • TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW
    • 12.1.12 INVIVOSCRIBE, INC.
    • TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
    • 12.1.13 AMOY DIAGNOSTICS CO., LTD.
    • TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW
    • 12.1.14 ELITECHGROUP
    • TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW
    • 12.1.15 VELA DIAGNOSTICS
    • TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 GENTRONIX LIMITED
    • 12.2.2 BIOIVT
    • 12.2.3 SAGA DIAGNOSTICS
    • 12.2.4 OLINK
    • 12.2.5 CANCER DIAGNOSTICS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS